Jim Lebenthal
Vertex Pharmaceuticals Inc.
VRTX-Q
PARTIAL SELL
Sep 11, 2023
A high-quality biopharma with a strong cystic fibrosis drug. Are trying to get into other franchises like diabetes treatments. Will do well long-run. Trades at 23x with 11% earnings growth, so you can take some profits now. Had a good run, so take some money off the table.
It's doing well, hitting new highs today. It's further along in its life cycle. Has a fine cystic fibrosis franchise. Shares are strong momentum, so he's staying in.
He likes it for developing non-addictive painkillers with potential FDA approvals ahead. They reported a great quarter a day before the election, but has since pulled back hard that baffles him. Looks like profit-taking in a stock that's jumped 113% since end-2021.
She trimmed it because it's up 20% this year because of the launch of their pain medicine. Tonight's earnings will be fine and their pipeline makes it a good stock long term.
He sold part of this. In Q1, the FDA approved a record low number of drugs, and Vertex has some important trials. Was nervous in a macro standpoint, but company fundamentals and valuation were reasonable. He hopes for a bounce.
Sold it. Long term this is great. He wrote a $19.50 covered call last Monday. Earnings slightly miss and the stock sold off. So, he hedged half the decline then got stopped out. It's pure risk management.
A high-quality biopharma with a strong cystic fibrosis drug. Are trying to get into other franchises like diabetes treatments. Will do well long-run. Trades at 23x with 11% earnings growth, so you can take some profits now. Had a good run, so take some money off the table.